Trial Profile

Targeted therapy with Imatinib for treatment of poor prognosis mesenchymal-type resectable colon cancer: a proof-of-concept study in the preoperative window period.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imatinib (Primary)
Indications Adenocarcinoma; Colon cancer
Focus Pharmacodynamics; Proof of concept
Acronyms ImPACCT

Most Recent Events

09 Oct 2019 Status changed from recruiting to discontinued.
07 May 2018 Planned End Date changed from 1 Dec 2018 to 1 Mar 2020.
07 May 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Nov 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com